症例報告
Influence of Long-term Abemaciclib, A New CDK 4/6 Inhibitor: Decrease in Liver Metastasis in a Patient Suffering from Metastatic Breast Cancer
Influence of Abemaciclib, a New CDK 4/6 Inhibitor, Decrease in Potassium Electrollytes and Urea in a Patient Suffering from Metastatic Breast Cancer
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi